These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19488608)

  • 1. The role of fecal calprotectin in investigating inflammatory bowel diseases.
    Erbayrak M; Turkay C; Eraslan E; Cetinkaya H; Kasapoglu B; Bektas M
    Clinics (Sao Paulo); 2009 May; 64(5):421-5. PubMed ID: 19488608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
    Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.
    Fagerberg UL; Lööf L; Myrdal U; Hansson LO; Finkel Y
    J Pediatr Gastroenterol Nutr; 2005 Apr; 40(4):450-5. PubMed ID: 15795593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Menees SB; Powell C; Kurlander J; Goel A; Chey WD
    Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
    Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive Correlation of Fecal Calprotectin With Serum Antioxidant Enzymes in Patients With Inflammatory Bowel Disease: Accidental Numerical Correlation or a New Finding?
    Vaghari-Tabari M; Moein S; Qujeq D; Kashifard M; Hajian-Tilaki K
    Am J Med Sci; 2018 May; 355(5):449-455. PubMed ID: 29753375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
    Li XG; Lu YM; Gu F; Yang XL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
    Hradsky O; Ohem J; Mitrova K; Durilova M; Kotalova R; Nevoral J; Kolho KL; Bronsky J
    Clin Lab; 2014; 60(12):1993-2000. PubMed ID: 25651733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.
    Kostakis ID; Cholidou KG; Vaiopoulos AG; Vlachos IS; Perrea D; Vaos G
    Dig Dis Sci; 2013 Feb; 58(2):309-19. PubMed ID: 22899243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin in inflammatory bowel diseases: update and perspectives.
    Manceau H; Chicha-Cattoir V; Puy H; Peoc'h K
    Clin Chem Lab Med; 2017 Mar; 55(4):474-483. PubMed ID: 27658156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fecal calprotectin in the assessment of intestinal inflammation in children with familial Mediterranean fever.
    Gucenmez OA; Kume T; Makay B; Babayigit O; Arslan N; Unsal E
    Int J Rheum Dis; 2018 Oct; 21(10):1844-1848. PubMed ID: 30345692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
    Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
    Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease.
    Sridhar M; Kesavelu D
    Indian Pediatr; 2019 Mar; 56(3):249-250. PubMed ID: 30955002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.
    Kok L; Elias SG; Witteman BJ; Goedhard JG; Muris JW; Moons KG; de Wit NJ
    Clin Chem; 2012 Jun; 58(6):989-98. PubMed ID: 22407858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.